Exact Sciences Drops $75M on Blood Test Like It’s Hot
In a move that screams 'We want it first or we want it all,' Exact Sciences is shelling out a whopping $75 million to snag exclusive rights to a blood-based 'liquid biopsy' from rival Freenome. Because nothing says friendly competition like locking down your neighbor's science project. To quote the deal, Exact Sciences is paying for 'exclusive rights'—so if you wanted a sneak peek at this fancy blood test, tough luck. Apparently, in the world of medical high-stakes poker, $75 million is just the ante.
Share the Story
(1 of 3)Exact Sciences just bought a blood test like it was the last Pumpkin Spice Latte. Exclusive rights for $75M proves medicine now prefers monopolies over miracles. Thanks, capitalism!
Nothing says friendship like a $75 million handshake to keep your rival’s blood test under lock and key. Science today: where billion-dollar block parties happen in lab coats.
Exact Sciences is basically the kid who snatches the shared toy and screams 'Mine!' but with $75 million. Blood tests have never been so possessive.
Source: Statnews | Published: 8/6/2025 | Author: Jonathan Wosen
More Articles in Health
Man Applies to 200 Jobs with AI's Help, Still Does Own Eyerolling
Motorola Razr Flip Phones Finally Told They’re Secure Enough for 2027
KPMG’s Consulting Business Dies Dramatically While Staff Take a Hike
90-Year-Old Dad Outsources Bathing to Jovial Nigerian and Ghanaian Carers
Woman Ages Backwards in Online Writing Class, Still Loses to 21-Year-Old
Billionaire’s Daughter’s Brain Hemorrhage Detected Belatedly By $299 Ring
Dietitians Unite to Demand We Eat More Beans, Save Humanity from Boredom
Mark Cuban Declares AI Too Empathetic to Replace Doctors, Only Bullshit Jobs Fear
